Hutchison China Meditech Ltd (HCM)

 

Latest News

Notification of Major Holdings

RNS Number: 2412V Hutchison China Meditech Limited 01 November 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached i...

NOTIFICATION OF MAJOR HOLDINGS

RNS Number: 2399V Hutchison China Meditech Limited 01 November 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Hutchison China MediTech Limited; Legal Entity Ide...

Chi-Med starts clinical trial of Inhibitor for gastric cancer patients

Hutchison China MediTech has initiated FRUTIGA, a pivotal phase III clinical trial of fruquintinib in combination with p...

FRUTIGA, a Phase III trial of Fruquintinib

RNS Number: 0641V Hutchison China Meditech Limited 31 October 2017 Press Release ChiMed Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line GastricCancer London: Tuesday , October 31 , 2017: Hutchison China MediTech Limited ("ChiMed") (AIM/Nasdaq: HCM) has initiated FRUTIGA , a pivotal Phase III clinical trial of fru quintinib in combin...

All News

DateHeadlineSource
01-11-17Notification of Major HoldingsRNS
01-11-17NOTIFICATION OF MAJOR HOLDINGSRNS
31-10-17Chi-Med starts clinical trial of Inhibitor for gastric cancer patients StockMarketWire
31-10-17FRUTIGA, a Phase III trial of FruquintinibRNS
30-10-17Closing of U.S. Public Offering of ADSsRNS
27-10-17Chi-Med Announces Over-allotment OptionRNS
26-10-17Chi-Med prices US public offering StockMarketWire
26-10-17Chi-Med Announces Pricing Raising US$262 millionRNS
25-10-17Chi-Med plans $262m offering on Nasdaq StockMarketWire
25-10-17Chi-Med Announces Proposed Offering of ADSsRNS
19-10-17Notification of Major Interest in SharesRNS
17-10-17Chi-Med and AZ present encouraging data on lung cancer drug StockMarketWire
17-10-17Savolitinib Shows Encouraging Clinical ActivityRNS
16-10-17Chi-Med reports 'promising data' on lung cancer drugStockMarketWire
16-10-17Chi-Med Reports Preliminary Phase II dataRNS
12-10-17Appointment of DirectorRNS
29-09-17Best AIM companies of 2017 Interactive Investor
29-09-17Savolitinib and Fruquintinib presentations at WCLCRNS
29-09-17Oral Presentations at CSCO Annual MeetingRNS
29-09-17Total Voting RightsRNS
31-08-17Director's Share DealingRNS
29-08-17Chi-Med starts clinical trial of Inhibitor in lymphoma patients StockMarketWire
29-08-17Start of HMPL 689 Phase I Trial in ChinaRNS
22-08-17Director's Share DealingRNS
18-08-17Directors' Share DealingRNS
15-08-17Directors' Share DealingRNS
10-08-17Director's Share DealingRNS
07-08-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
07-08-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
07-08-17Directors' Share DealingRNS
31-07-17Chi-Med revenues up 21%StockMarketWire
31-07-17Chi-Med Reports 2017 Interim ResultsRNS
30-06-17Total Voting RightsRNS
29-06-17Chi-Med and AZ start global trial of renal cancer drug StockMarketWire
29-06-17Start of Savolitinib Global PRCC Phase III TrialRNS
29-06-17Chi-Med to Announce 2017 HY Financial ResultsRNS
29-06-17Blocklisting Six Monthly ReturnRNS
22-06-17Chi-Med starts clinical trial in China StockMarketWire
22-06-17Chi-Med starts Ph I/II Trial of HMPL 453 in ChinaRNS
16-06-17Director's Share DealingRNS

RSS feeds

  • Editorial news feed for LSE:HCM Editorial
  • Regulatory news feed for LSE:HCM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account